Richard Boyd Barrett (Dún Laoghaire, People Before Profit Alliance)
Link to this: Individually | In context | Oireachtas source

431. To ask the Minister for Health if, in view of the National Centre for Pharmaco-Economics report that the drug Orkambi prolongs life by a median 7.4 years, 2.45 QALY and the cost-effectiveness threshold of €30,000 per annum, if he will advise of the average cost and lowest cost per annum charged for the drug in the EU; if the HSE will make an offer to the manufacturer in view of these facts; and if he will make a statement on the matter. [35958/16]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.